Kevin Carroll

3.3k total citations · 1 hit paper
29 papers, 2.3k citations indexed

About

Kevin Carroll is a scholar working on Nephrology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Kevin Carroll has authored 29 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Nephrology, 7 papers in Surgery and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Kevin Carroll's work include Renal Diseases and Glomerulopathies (9 papers), Statistical Methods in Clinical Trials (5 papers) and Chronic Kidney Disease and Diabetes (3 papers). Kevin Carroll is often cited by papers focused on Renal Diseases and Glomerulopathies (9 papers), Statistical Methods in Clinical Trials (5 papers) and Chronic Kidney Disease and Diabetes (3 papers). Kevin Carroll collaborates with scholars based in United Kingdom, United States and Germany. Kevin Carroll's co-authors include Tudor–Eliade Ciuleanu, E.H. Tan, Venice Archer, Joachim von Pawel, Nick Thatcher, Kristine Pemberton, Alex Y. Chang, José Rodrigues Pereira, Sumitra Thongprasert and Purvish M. Parikh and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

Kevin Carroll

26 papers receiving 2.2k citations

Hit Papers

Gefitinib plus best suppo... 2005 2026 2012 2019 2005 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    2005 1.7k citations Nick Thatcher, Alex Y. Chang et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Carroll United Kingdom 9 1.5k 1.3k 396 283 275 29 2.3k
Young Hak Kim Japan 30 1.7k 1.1× 1.9k 1.5× 644 1.6× 60 0.2× 279 1.0× 127 2.8k
Pascaline Boudou‐Rouquette France 29 1.2k 0.8× 1.4k 1.1× 644 1.6× 134 0.5× 323 1.2× 133 2.9k
Jamal Tarazi United States 24 2.0k 1.3× 1.0k 0.8× 1.4k 3.6× 118 0.4× 960 3.5× 65 2.6k
Bertrand Billemont France 19 658 0.4× 423 0.3× 596 1.5× 94 0.3× 246 0.9× 39 1.4k
Yazdi K. Pithavala United States 25 1.2k 0.8× 1.1k 0.8× 1.2k 2.9× 124 0.4× 581 2.1× 65 2.5k
M. Brent McHenry United States 24 1.4k 0.9× 1.9k 1.4× 602 1.5× 91 0.3× 444 1.6× 42 2.8k
Siu‐Long Yao United States 18 1.0k 0.7× 700 0.5× 459 1.2× 121 0.4× 483 1.8× 43 2.0k
Sibyl Anderson United States 19 1.2k 0.8× 695 0.5× 944 2.4× 124 0.4× 524 1.9× 40 2.1k
Joel Jiang United States 16 650 0.4× 2.4k 1.9× 964 2.4× 104 0.4× 137 0.5× 24 3.6k
Eugene R. Ahn United States 22 346 0.2× 604 0.5× 443 1.1× 126 0.4× 331 1.2× 78 1.6k

Countries citing papers authored by Kevin Carroll

Since Specialization
Citations

This map shows the geographic impact of Kevin Carroll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Carroll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Carroll more than expected).

Fields of papers citing papers by Kevin Carroll

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Carroll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Carroll. The network helps show where Kevin Carroll may publish in the future.

Co-authorship network of co-authors of Kevin Carroll

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Carroll. A scholar is included among the top collaborators of Kevin Carroll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Carroll. Kevin Carroll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Alan S.L., Keith Bellovich, Claire Padgett, et al.. (2024). RGLS8429 Increases Urinary PC1 and PC2 and May Reduce Height-Adjusted Total Kidney Volume (htTKV) in Patients with ADPKD. Journal of the American Society of Nephrology. 35(10S).
2.
Trimarchi, Hernán, Jonathan Barratt, Hiddo J.L. Heerspink, et al.. (2024). #1021 A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy. Nephrology Dialysis Transplantation. 39(Supplement_1). 2 indexed citations
3.
Weber, Frank, Mickaël Schaeffer, Antje Meyer, et al.. (2024). Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD). Journal of the American Society of Nephrology. 35(10S).
4.
Carroll, Kevin, et al.. (2023). Hemodialysis catheter-related right atrial thrombus treated with the FlowTriever system. Journal of Vascular Surgery Cases and Innovative Techniques. 9(4). 101318–101318. 1 indexed citations
5.
Mercer, Alex, Kevin Carroll, Bruce M. Hendry, et al.. (2023). #4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations
6.
7.
Rizk, Dana V., Vlado Perkovic, Richard Lafayette, et al.. (2022). A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy. Journal of the American Society of Nephrology. 33(11S). 799–799. 2 indexed citations
8.
Singh, Ajay, Finnian R. Mc Causland, Brian Claggett, et al.. (2022). Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation. 38(8). 1890–1897. 8 indexed citations
9.
Lafayette, Richard, Kevin Carroll, & Jonathan Barratt. (2021). Long-Term Phase 2 Efficacy of the MASP-2 Inhibitor Narsoplimab for Treatment of Severe IgA Nephropathy. Journal of the American Society of Nephrology. 32(10S). B10–B10. 2 indexed citations
10.
11.
Thompson, Aliza, Kevin Carroll, Lesley A. Inker, et al.. (2019). Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 14(3). 469–481. 161 indexed citations
12.
Delafont, Bruno, Kevin Carroll, Claire Vilain, & Emmanuel Pham. (2018). Investigation of mixed model repeated measures analyses and non‐linear random coefficient models in the context of long‐term efficacy data. Pharmaceutical Statistics. 17(5). 515–526. 2 indexed citations
13.
Zhang, Peter, et al.. (2017). A case study in identifying targeted patients population in major depressive disorder by enhanced enrichment design. Pharmaceutical Statistics. 17(2). 144–154. 1 indexed citations
14.
Getz, Elise Burmeister & Kevin Carroll. (2017). Pharmacokinetic Bioequivalence of Two Fluticasone Propionate/Salmeterol Dry Powder Inhalers, OT329 Solis, and Advair Diskus. CHEST Journal. 152(4). A768–A768. 1 indexed citations
15.
Carroll, Kevin & Robert Hemmings. (2016). On the need for increased rigour and care in the conduct and interpretation of network meta‐analyses in drug development. Pharmaceutical Statistics. 15(2). 135–142. 8 indexed citations
16.
Mahaffey, Kenneth W., Daniel Wojdyla, Kevin Carroll, et al.. (2011). Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 124(5). 544–554. 287 indexed citations
17.
Carroll, Kevin, S. Krishna Padmanabhan, & Andrew Stone. (2009). Literature Review October–December 2008. Pharmaceutical Statistics. 8(1). 84–86. 3 indexed citations
18.
Carroll, Kevin, et al.. (2007). Conditional approval: discussion points from the PSI conditional approval expert group. Pharmaceutical Statistics. 7(4). 263–269. 5 indexed citations
19.
Stone, Andrew, Catherine Wheeler, Kevin Carroll, & Alan Barge. (2006). Optimizing randomized phase II trials assessing tumor progression. Contemporary Clinical Trials. 28(2). 146–152. 19 indexed citations
20.
Thatcher, Nick, Alex Y. Chang, Purvish M. Parikh, et al.. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). The Lancet. 366(9496). 1527–1537. 1688 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Young Hak Kim Breakdown of academic impact, for papers by Pascaline Boudou‐Rouquette Breakdown of academic impact, for papers by Jamal Tarazi Breakdown of academic impact, for papers by Bertrand Billemont Breakdown of academic impact, for papers by Yazdi K. Pithavala Breakdown of academic impact, for papers by M. Brent McHenry Breakdown of academic impact, for papers by Siu‐Long Yao Breakdown of academic impact, for papers by Sibyl Anderson Breakdown of academic impact, for papers by Joel Jiang Breakdown of academic impact, for papers by Eugene R. Ahn
Rankless by CCL
2026